沙格雷酯与西洛他唑治疗2型糖尿病下肢血管病变的临床对照研究  

Effect of sarpogrelate (Anplag) versus cilostazol on the peripheral artery disease in patients with type 2 diabetes:A randomized and controlled trial

作　　者：吴心池[1] 施广德[1] 黄文龙[1] 张晓兰[1] 方铭[1] 

机构地区：[1]江阴市人民医院内分泌科,江苏214400

出　　处：《中国糖尿病杂志》2010年第8期607-610,共4页Chinese Journal of Diabetes

摘　　要：目的观察沙格雷酯治疗糖尿病下肢血管病变的效果。方法 40例患者按1:1随机进入沙格雷酯组(20例)和西洛他唑组(20例)。沙格雷酯用量为300mg/d,西洛他唑100mg/d,共两个月。比较两组治疗前后及其组间下肢血管病变、神经病变的症状、无痛行走距离、能耐受疼痛的最大行走距离和踝/肱血压指数(ABI)。结果沙格雷酯组主观症状明显改善,最大行走和无痛行走距离、ABI及足背动脉血管流速均显著增加。结论沙格雷酯对糖尿病下肢血管病变是一种安全有效的药物。Objective To study the effect of sarpogrelate （Anplag） treatment on the peripheral artery diseases （PAD） in patients with type 2 diabetes. Methods Forty diabetic patients with PAD were randomized into 2 groups. Sarpogrelate group （n= 20,300 mg daily, SGL） and Cilostazol （n = 20,100mg daily,CLT） for 8 weeks. Both pain-free and maximal walking distance, ankle-branchial blood pressure index （ABI）, and ultrasonic angiography image of the peripheral vessels were compared before and after the treatment between CLT and SGL groups. Results Obvious improvement of the symptoms was found, the pain-free and maximal walking distance, ABI and velocity of bloodstream were increased after treatment with sarpogrelate versus eilostazol. Conclusions Sarpogrelate is safe and effective when used in the treatment of the peripheral artery diseases （PAD） in the patients with type 2 diabetes.

关 键 词：糖尿病 下肢血管病变 沙格雷酯 西洛他唑 

分 类 号：R587.2[医药卫生—内分泌]